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ACRONYMS 
AIDS:      Acquired Immune Deficiency Syndrome 
ANC:       Antenatal Care 
ART:      Anti-Retroviral Therapy 
ARV:             Anti-Retroviral    
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H AART:   Highly Active Anti-Retroviral Treatment 
HIV:               Human Immunodeficiency Virus 
MSF:             Medecins Sans Frontiers  
MTCT:        Mother to Child Transmission  
NHC:         Nhlangano Health Centre 
OVC:          Orphaned and Vulnerable Children 
PMTCT:      Prevention of Mother to Child Transmission of HIV 
STIs:           Sexually Transmitted Infections 
TB:               Tuberculosis 
WHO:           World Health Organisation 
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PROJECT TITLE      
Acceptance of and adherence to full anti-retroviral therapy for prevention of 
mother to child transmission in HIV infected pregnant women with CD4 count 
above 350 at Nhlangano Health Centre, Swaziland. 
 
ABSTRACT    
Epidemic of HIV infection is hitting Swaziland where the prevalence is among 
the highest in the world. Nhlangano Health Centre (NHC) in collaboration with 
Medecins Sans Frontiers Switzerland (MSF Switzerland) opted to hit early by 
starting Highly Active Anti-retroviral Therapy (HAART) among HIV infected 
pregnant women with CD4 count cells above 350. This new intervention raised 
concerns on acceptability and adherence which needed to be assessed. 
Study design: 
This was a descriptive study which explored the acceptance of and adherence 
of pregnant women to full anti-retroviral therapy at Nhlangano Health Centre in 
the period from 24th June 2014 to 23rd June 2015. The level of adherence was 
assessed by announced pill counts on subsequent visits. Then, 6 months after 
initiation, the viral load and a second CD4 count were determined. 
Results: 
98 participants were recruited and initiated; one later died. 80.6% resided in the 
rural area. 80.6% attended secondary school. Majority were single (79.6%). 
Mean age was 25.4 years. 64.3% booked at 2nd trimester. Most were 
multiparous (75.5%). Mean haemoglobin was 11.1g/dl. After 6 months, mean 
CD4 count was 709.4 up from 554.4 (initial) and 66 (95.6%) had undetectable 
viral load risen from 14 (20.2%) at initiation. 69 participants (70.4%) were 
adherent to treatment; 3 (3.1%) of them failed to suppress completely the viral 
loads. 13 pregnant women refused HAART; of these 12 were interviewed and 
one declined. The rate of acceptance was 88.3%. 
 Conclusion: 
Most of the HIV infected pregnant women who visited the clinic accepted the 
treatment, their CD4 count increased and had undetectable viral loads after 6 
months. Anti-retroviral therapy is effective and can be successfully initiated in 
pregnant women with CD4 count above 350 but should be monitored closely to 
avoid loss to follow-up.  
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INTRODUCTION    
Highly active antiretroviral therapy (HAART) has dramatically changed HIV-
related morbidity and mortality and has improved the quality of life of HIV-
infected individuals. Of recent, a lot of effort is being put in to expand access to 
HIV treatment in resource-limited settings.1  
Swaziland is a developing sub-Saharan country with limited medical resources. 
In 2009, it had the highest adult HIV prevalence in the world. An estimated 
25.9% (24.9% - 27%) of people in the country were living with HIV. Nationally, 
all women have heard about HIV but only 59% of women and 55% of men have 
a comprehensive knowledge about HIV prevention according to the final report 
of multiple indicator cluster survey MICS, 2010. In 2007, Swaziland had 56, 000 
orphans (aged 0 - 17) as a result of AIDS.2 
A majority of pregnant women living with HIV in the world are from sub-Saharan 
Africa; an estimated 68% of them received antiretroviral therapy prophylaxis 
during pregnancy and delivery in 2013.3Nationally, the proportion of Orphaned 
and Vulnerable Children (OVC) is 45%, 24% are single or double orphans and 
the prevalence of orphaned underage with at least one dead  parent  is 26.6%.4 
This constitutes a social burden for the extended family, which has the 
traditional responsibility to care for orphans. 
The challenges associated with effective prevention of mother-to-child 
transmission of HIV (PMTCT) and measuring its impact are numerous and 
multi-factorial3. It is well known that most of HIV infected infants in Africa 
acquire the disease from their mothers during pregnancy, at the time of delivery 
or post- natal through breast-feeding and the risk of transmission for a child 
born to an HIV infected mother without PMTCT interventions is high.  In South 
Africa, with 5.6 million people living with HIV, 330 000 of these were paediatric 
infections largely due to mother to child transmission.  Out of 38 000 as at mid-
2006; 26 000 subsequently got HIV-infected through breast-feeding.5 Routine 
testing is a crucial step and precedes initiation of ART. The objective is to 
achieve universal access to focused antenatal health care and also promote 
healthy neonatal and maternal outcomes.3 In the mother to child HIV prevention 
care, pregnant women also face challenges like fears of knowing one’s own 
HIV status, infant feeding distribution, stigma, discrimination, lack of male 
partners’ support and negative attitude of health workers.6 
Furthermore, in Uganda, most pregnant women emphasized the importance of 
their partners in decision making and the access of antiretroviral therapy.7 
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Between 2000 and 2009, there was a 24% reduction in the estimated annual 
number of new child infections in 25 African countries of which about one third 
occurred in 2009 alone by providing PMTCT interventions8. Antiretroviral 
therapy (ART) has saved many lives by transforming HIV infection from a fatal 
into a chronic disease9. 
Currently, a short course of antiretroviral therapy is being offered by all ANC 
government services in Swaziland. 
Despite availability of free antiretroviral therapy, in Malawi, they noted a 
progressive loss to follow up of HIV infected women by the postnatal visits 
which challenged the PMTC programme10. Good adherence to treatment 
reduces the risk of mother to child transmission. 
ART has been proven safe and effective in reducing rates of MTCT by 
providing maternal viral suppression and decreasing infant mortality.11,12 
Furthermore, more than 6 in 10 pregnant HIV positive women with CD4 cell 
count of > 350/mm3 may require triple antiretroviral for prophylaxis of MTCT13 
Two basic approaches to the use of ART for PMTCT are recommended in 
government health institutions; HAART and ART prophylaxis. HAART is for HIV 
positive pregnant women in need of treatment; their CD4 count is below 350 or 
in stage 3 or in stage 4 by WHO clinical stage. Whereas, ART Prophylaxis is for 
those who don’t need the treatment for their own health; it’s a short course of 
anti-retroviral therapy given from 14 weeks of gestation or as soon as possible 
thereafter. 
Mother-to-child transmission (MTCT) is estimated to be the cause of at least 
90% of paediatric HIV infections. WHO guidelines for the prevention of  
perinatal transmission in low-resource settings recommend using HAART for 
pregnant women in need of ART for their own health14.  In 2013, a new regimen 
in our program of prevention of mother to child HIV transmission (MTCT) in 
collaboration with MSF was launched in NHC in Swaziland where all pregnant 
women found positive despite their CD4 count cells level will be started on 
lifelong  triple therapy (TDF-3TC-EFV) and 6 weeks of nevirapine will be given 
to the baby.  This regimen reduces the number of women eligible for ART who 
don’t receive ART, avoids the use of nevirapine for a long period and protects 
infants from an early stage. Concerns over acceptance of initiation and 
adherence are being portrayed in healthy pregnant women with high CD4 
count15 . 
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Adherence to ART is critical for achieving therapeutic success in the treatment 
of HIV infection. There is no widely acceptable professional consensus for 
measuring adherence. Several methods have been used with varying success. 
The indirect methods of self-report and pill counts are quick and inexpensive16 
Aim      
The aim of this study was to explore the acceptability of and adherence to full 
antiretroviral therapy to HIV infected pregnant women with high CD4 count cells 
in order to prevent mother-to-child transmission. 
Objectives     
To assess the acceptance level of HAART among pregnant women with CD4 
count above 350 in NHC                                                                                                                 
To assess the adherence level of HAART among pregnant women with CD4 
count above 350 in NHC                                                                                                                    
To find and list the main reasons for refusal of full antiretroviral therapy among 
pregnant women with CD4 count above 350.        
 
METHODS      
Study design     
This was a prospective observational cohort study carried out in the period from 
24th June, 2014 to 23rd June, 2015. 
 
Setting 
Swaziland is a small country located in south east Africa with Mozambique to 
the east and South Africa on all other borders. The total land area is 17 
364.50km2 with a population of 1 018 449 people who primarily reside in rural 
areas.17  The birth rate is 3.7 and HIV prevalence is 26%.Nationally, 80% of 
deliveries occur in health facilities and 82 per cent of pregnant women are 
delivered babies with the assistance of skilled personnel. 
The health care programmes in Swaziland are co-ordinated at the central level 
by the ministry of health and at regional level by the Regional health 
management team. The government health care system is divided into 3 levels 
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namely clinics, the first level of primary healthcare, health centres (HC) and 
public health units, the second level and hospitals, the last level. 
The country is divided into 4 administrative regions which include Shiselweni in 
the South. The main town in the Shiselweni region is Nhlangano. The study 
was conducted in Nhlangano Health Centre where I am a practising doctor.   
It is a health centre 35km away from the regional referral hospital with 70 beds. 
It has a maternity ward with 700 deliveries per annum, female/male ward, 
children ward, and outpatient department, TB/MDR ward and a public health 
unit which runs immunizations, family planning(FP), antenatal and postnatal 
care activities. 
The health centre also serves as a secondary referral centre for 7 clinics in this 
region and has been very helpful to the community of Nhlangano and 
surroundings. The catchment area of the centre is estimated at 1,558 square 
km for a population of 9 017. 
Study population     
It was a restricted population with only ART-naive HIV-infected pregnant 
women with CD4 count above 350 seen at the public health unit of NHC. 
The sample population was of those who attended the ante-natal clinic between 
24th June 2014 and 23rd June 2015; a time period of one year.  In this period, 
277 HIV infected pregnant women with CD4 count above 350 were seen; 111 
(40.1%) met the inclusion criteria. The 111 pregnant women who met the 
criteria were approached to participate in the study; 98 accepted and 13 
declined.  
Inclusion criteria:  ART-naive HIV infected pregnant women with CD4 count 
above 350. 
Exclusion criteria:  Women already on HAART with CD4 count above 350 
who fell pregnant.  Women who took short course of antiretroviral prophylaxis 
during their previous pregnancy. Women who had renal failure and CD4 count 
above 350. 
Data collection     
All pregnant women who agreed to test after counselling were screened for HIV 
antibodies. When a positive result was confirmed after the screening test, a 
CD4 count, a liver function test (ALT and AST) and a renal function test 
(Creatinine and Urea) were requested by the nurses at the NHC. Thereafter, 
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the nurses at NHC initiated HAART or ART prophylaxis. All those who had an 
initial CD4 count above 350 and with no renal failure were approached for their 
consent to participate in this research. Thereafter, the patient was expected to 
visit the clinic on a monthly basis up to 6 months after initiation. The patients 
were tested for CD4 count at baseline and 6 months, viral load at baseline and 
6 months, full blood count at baseline, one month and 6 months, both liver 
function tests and renal function tests at baseline, one month, 3 months and 6 
months. During the study, adherence was assessed on the basis of announced 
pill count on the monthly review visit days. At 6 months after initiation, all the 
participants in the study were tested for viral load and CD4 count to evaluate 
their adherence level. All the costs for the tests were borne by MSF and 
government. 
Socio-economic and demographic data was collected at baseline; on the date 
of treatment initiation. Data required for the study such as viral load and CD4 
count was routinely collected during the regular ante-natal and post-natal visits. 
So, at the end of the study, routine data from ANC, post-natal, ART and 
laboratory registers was reviewed. At the end of the day, the number of patients 
attended to was equal to the number of files which appeared and the details of 
therapy were counter-checked by nurses in the patient files and the ART 
register to avoid omissions and disparities. The researcher cross-checked this 
on a monthly basis; this was to ensure that the cross-checking which was done 
by nurses was accurate and up to expectations.   
Patients who refused on the offer of HAART were interviewed by nurses who 
had been trained prior to research initiation; to ensure standardisation. A 
structured interviewer administered questionnaire was completed.  
The questionnaire had two parts. The first part had questions on socio-
economic and demographic factors like age, marital status, education level, 
religion and employment status; to be completed for all participants. The 
second part had a series of open-ended questions categorised according to 
PMTCT programme knowledge, counselling experience, barriers to 
participation in the PMTCT programme and possible ways to overcome them.  
Data analysis     
The analysis focused on evaluation of the acceptance and adherence level to 
the medication based on announced pill counts. Individual adherence level was 
evaluated in the manner indicated below (Table 1). 
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Table1: Adherence level by percentage. 
Category  % 
Missed one day           95      
Missed 3 days    90                                                                                                                                         
Missed one week                80    
Missed 10 days            70                                                                                                                                                  
Missed 2 weeks            50      
Missed 3 weeks  20 
 
Analysis between viral load results, progression of CD4 count results and 
reported adherence level was done and summary statistics were reported as 
frequencies and percentages. Total adherence to ARV regimen increases CD4 
count and suboptimal adherence leads to incomplete viral suppression and 
delays immune recovery. A significant drop in viral load and a substantial 
increase in CD4 count were and are associated with a high level of adherence.                                                                                                      
The reasons given by patients for refusal of HAART were categorised and 
tabulated.    
The patients who refused HAART underwent individual semi-structured 
interviews which were recorded in siswati. The interviews were transcribed and 
translated into English.  Due to the need for confidentiality, no names were 
used. The transcripts were re-read and coded. The codes were manually sorted 
into categories using cells in MS excel and the main themes emerged.  
Ethical considerations 
This study obtained the permission of Health Research Ethics Committee of 
Stellenbosch University (Ethics reference number S13/08/152) and the 
Swaziland Ethics Committee (MH/599C/FWA0001526). Informed consent was 
given prior to participation. 
RESULTS    
Patients’ characteristics     
A total of 98 ART-naive HIV-infected pregnant women were recruited and 
followed up for 6 months between 24thJune, 2014 and 23rd June, 2015. 78 
(79.6%) of the participants were single and 20 (20.4%) were married (Table 5). 
Most of the effected pregnant women were Christians 96 (98%), only 2% were 
not Christians (Table 6). Their other socioeconomic and demographic factors 
such as age, education level, employment status are detailed below. 
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Residence 
Nhlangano (NHO) is composed of NHO CBD and urban residential areas 
administered by NHO town council (Figure 1) and 14 Tinkhundla (surrounding 
areas); Zombodze, Maseyisini, Sigwe, Mtsambama, Shiselweni 1, Shiselweni 
2, Hosea, Sandleni, Kubuta,  Matsanjeni, Gege, Ngudzeni, Nkwene and 
Somtongo administered by the traditional government. 
The map below shows the position of Nhlangano town and its surrounding rural 
and hinterland with boundaries: Gege, Mahamba, Mhlosheni and Hlathikhulu.  
 
Figure 1: Shiselweni Region  
Source: Swaziland’s Official Tourist Guide 2013/4 (Swaziland Discovery)  
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Table 2 : Percentage distribution of participants by residence. 
 
Most of the infected pregnant women reside outside NHO town; in the rural 
areas (81.6%). Only 19.4% reside in NHO residential areas(Table 2). 
 
Employment         
Table 3 : Percentage distribution of participants by status of employment. 
Status of employment Frequency Percentage (%) 
Unemployment 47  48 
Employment 51  52 
Total 98 100 
 
Nhlangano is a semi-urban area offering employment mainly in textile firms. Of 
the 51 (52.0%) employed (Table 3), 39 (76.5%) were employed in the textile 
firms (machinists, dressmakers and trimmers), 9 (17.6%) were employed as 
either labourers or housekeepers, the rest (5.9%) were: one cashier, one police 
officer and one self-employed in a small-scale business. Apart from the police 
officer, the rest were employed in low income earning jobs. Female 
unemployment rate in Swaziland is 25.60% (World Bank, 2013).18 
 
 
 
Residence Frequency Percentage (%) 
NHO Town 19 19.4 
Maseyisini 42 42.9 
Shiselweni1   3   3.1 
Shiselweni2 22  22.4 
Zombodze   8    8.2 
Hosea   1    1 
Sandleni   1    1 
Matsanjeni   1    1 
Other region(Manzini)   1    1 
Total 98 100 
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Education    
Table 4 : Percentage distribution by level of education. 
Level of education Frequency Percentage (%) 
None  1   1 
Primary school 13 13.3 
Secondary School 79  80.6 
Tertiary   5    5.1 
Total 98 100 
 
The majority of the infected pregnant women had at least attended secondary 
school (85.7%).19 Only 1% never attended school. The transition rate to 
secondary school of 85.5% is reported for Swaziland (Swaziland Multiple 
Indicator Cluster Survey 2014).20 
 
Marital Status      
Table 5 : Percentage distribution by marital status. 
Marital status Frequency Percentage (%) 
Single 78  79.6 
Married 20  20.4 
Total 98 100 
 
 
Religion       
Table 6 : Percentage distribution by religion. 
Religion Frequency Percentage 
Christian 96  98 
Non-Christian   2    2 
Total 98 100 
 
 Age        
The 98 infected pregnant women had ages ranging from 17 to 38 years with a 
mean age of 25.4 years. The majority of the infected pregnant women fell in 
this age bracket so most interventions should be focused on this group. This 
age group needs more close follow up during prevention. 
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Table 7 : Percentage distribution by age. 
Age Frequency Percentage (%) 
15-19   8     8.1 
20-24 39   39.8 
25-29 32   32.7 
30-34 14   14.3 
35-39   5     5.1 
≥40   0     0 
Total 98 100 
 
 
Figure 2 : Proportion of participants by age 
 
Gestational age at presentation at NHC 
Table 8 : Percentage distribution by gestational age. 
Trimester Frequency Percentage 
First trimester  9    9.2 
Second trimester 63  64.3 
Third trimester 26  26.3 
Total 98 100 
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63 (64.3%) of infected pregnant women had the first visit during the second 
trimester. Only 9.2% attended in their first trimester(Table 8) . This is in 
accordance with WHO Survey data from sub-Saharan Africa which indicated 
that women initiated antenatal care after the first trimester despite the guideline 
of Swazi Ministry of Health which advises to start ANC as soon as the woman 
knows that she is pregnant21,22. 
Gravidity      
Table 9 : Percentage distribution of participants by gravidity. 
Gravidity Frequency Percentage (%) 
1 21  21.4 
2-4 74  75.5 
≥5   3    3.1 
Total 98 100 
 
Most of the participants were multiparous 77(78.6%).Parity and past pregnancy 
experiences affect ANC initiation. In general, multiparous women attend ANC 
later compared to primigravida 21(21.4%). Multiparous tend to delay ANC 
initiation to avoid multiple clinic visits.  
 
Haemoglobin       
Table 10 : Percentage distribution by haemoglobin level. 
Haemoglobin Frequency Percentage 
>11 g/dl 59  60.2 
10,0-10.9 g/dl 17  17.3 
7.0- 9.9 g/dl 22  22.5 
<7.0 g/dl  0     0 
Total 98 100 
 
 Anaemia in pregnancy is defined as haemoglobin reading below 7.0 g/dl 
(grams per decilitre). According to the World Health Organization, anaemia is 
classified as mild (10.0-10.9g/d), moderate (7.0-9.9g/dl) and severe (less than 7 
g/dl). 
The haemoglobin of the participants varied between 7g/dl and 15.2g/dl with an 
estimated mean haemoglobin of 11.1 g/dl. 39(39.8%) were anaemic but no one 
had severe anaemia. This might have given them a false impression that they 
were well. 
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Follow up visits     
Attendance       
Table 11 : Attendance of participants.  
 Attendance 
At initiation 98     
First month after initiation 79 
Six months later 69 
 
One month after initiation 79 (80.6%) participants attended the first 
appointment, 19 (19.4%) didn’t.  Six months later:   
 69 (70.4%) infected pregnant women were still in attendance for refill 
monthly. Pill counts were conducted at each visit(Table 11). 
 29 (29.6%) were not. Of these, 16 (16.3%) never completed the 6 
monthly visits (loss to follow up), 12 (12.2%) patients were referred (3 
formally, 9 self-referred to other facilities) and 1 (1.0%) patient died. 
All of the remaining 69 (70.4%) were adherent; adherence level was above 
95% 
 
   Figure 3 : Proportion distribution by attendance.                       
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CD4 Count        
The initial mean CD4 Count of adherent pregnant women was 554.4. After 6 
months, the mean CD4 Count was 709.4. 
Viral load        
Viral load is undetectable if viral load is equal to or less than 100 copies per ml. 
Table 12 : Comparison of viral load; at base and final of the 69 adherent pregnant women. 
 Detectable Viral Load Undetectable Viral load 
Initial 55 14 
After 6 months   3 66 
                                             
At initiation, of the 69 adherent pregnant women, 14 (20.2%) had undetectable 
viral load and 55 (79.8%) had detectable viral load. After 6 months, 66 (95.6%) 
of the adherent pregnant women had undetectable viral load; 3 (4.4%) had 
detectable viral load (Table12). 
 
    
Figure 4 : Comparison of viral load at baseline and after 6 months for the 69 adherent pregnant 
women. 
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 Acceptance rate 
In our study, 98 participants agreed to be on HAART and were initiated. 13 
pregnant women refused the treatment; 12 of these were interviewed and one 
declined. The rate of acceptance was 88.3 %. 
Reasons for refusal     
Characteristics of respondents       
They had similar characteristics to the group that had accepted treatment. Their 
ages ranged between 18-35 years. Most of them were single and Christians. 
They had limited education as none had completed high school. They were 
also unemployed; dependent on partners and family for financial support. A 
number of the women were familiar with the ANC services as they had in the 
past repeatedly visited the health facility to seek ANC services. One of the 
respondents had been living with HIV for 11 years, but still refused to enroll on 
ART for PMTCT. 
        “In 2004, I was told I had it (HIV virus). I had just come to get tested (001)”. 
Knowledge on HIV transmission and treatment (care)       
HIV transmission 
A number of respondents said that HIV was transmitted through intercourse. A 
few went further to specify that it was transmitted through sexual intercourse 
with an infected person. 
“I  know that it is transmitted through sexual intercourse. Having intercourse with          
someone who already has it (001)” 
“Getting into bed…sex…when the fluids mix and one of them is positive ( 010)”.  
“By having intercourse and by…what can I say…through blood (012). “ 
Another factor that was mentioned was touching someone else’s blood who is 
hurt or bleeding with unprotected hands. 
              “When you touch someone else’s blood, an injured and bleeding person; touching the 
person with bare hands (010)”.  
 
Mother to child transmission (MTC)          
Stellenbosch University  https://scholar.sun.ac.za
20 
The most prominently discussed modes of HIV transmission from mother to 
child are during delivery and breast feeding. Of note is that these factors were 
only mentioned when specifically probed on mother to child HIV transmission.  
 
“When he is being delivered…or when breast feeding…or giving complimentary 
feeding. It’s that… when the baby gets hurt while still trying to breast feed. And 
then…he (baby) gets infected (001)”.  
The women displayed lack of understanding of HIV transmission from mother to 
child during pregnancy.  
 
      “While pregnant, I think the baby gets infected when not using a condom (001) “ 
Importance and benefits of ART/PMTCT       
Most of the women reported that they didn’t know the importance and benefits 
of ART when pregnant or lactating.  However, the benefits that were mentioned 
included the ability of ART to suppress viral load.  
     “No. I don’t. I know that it (HIV) is curable, not curable but it is suppress   pills are 
taken (011)”.  
     “They help me in that they prevent me from infecting the child with the 
virus. From the time they are in the womb till I give birth (004)”.  
“When taking the pills… the soldiers (CD4 count) increase (006)”.  
“I benefit in the sense that he (baby) might come out negative and I will 
live, secondly, you find that you die because of not taking the pills or 
not (sound of opening door) getting the right treatment (009)”. 
Lack of counseling on ART       
A majority of the women indicated that they had received no counselling or 
received little counselling on ART.  The ones who indicated to have received 
counselling said they were only told that enrolling on ART will protect the baby 
from being infected with HIV. A few mentioned having been told about the 
importance of adhering to taking ARVs at the same time every day lest they 
become resistant and also the importance of eating healthy. 
     
            “They never explained much to me, they just said that I should go take pills and I 
refused to take them, I just refused, (silence). I refused. They never said 
much to me (010)”.  
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             “ From South Africa, I had gone for check-ups. They wrote the pills in the card. 
They said they are for protecting the baby. My CD4 was still ok (004)”. 
  
           “Yes. I asked them in the caravan since we were in a caravan, why my CD4 has 
increased in the period and I never got any response. They then said they 
can’t deal with me because of the questions that I ask. Ok…I let go just like 
that. I then asked them (health workers) at what level should the CD4 be to 
be considered to be at a healthy state and I was not answered on that one. 
They never answered me. I then listened to the AIDS programmes from radios 
where they mentioned that some people have a low CD4 count and others 
have a high CD4count (001)”.  
 
Barriers to ART uptake       
Fear of side effects 
Another barrier that was raised by the women was fear of ART side effects and 
these were issues which they had heard from other people such as relatives.  
The most cited side effect was not feeling well or getting sicker when taking 
ART.   
“There are some instances where people say that sometimes one can be 
requested to change (switch) them. I have a cousin who tried to switch them 
and got sick; sickness re-occurred until she was bedridden ( 002)”. 
          “In general, the pills make one feel not well all the time (002)”. 
           “Some people, I hear, say that the pills make them more sick (002)”.   
          “They say it doesn’t treat others well, you find that when they take it, they 
throw-up (009)”. 
Use of alternative traditional medicine  
Some of the women didn’t enroll on ART because they were taking traditional 
medicine (Timbita) which they believe functions in a similar way as ART. 
“I think that it will help in general; in the same way that the pills do (002)”. 
 
                   “I was going to talk to my partner first. He told me that there was some traditional 
brew that he was going to give me so I shouldn’t take them (pills) (004)”. 
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                  “I am not refusing it’s just that I live with people and they are still taking me to 
places with this sickness that I have. I don’t know if it will work well with the pills, 
because they (family) are taking me places. (012)”. 
 
Challenges in accepting HIV Status  
There was also evidence that some of the women refused enrolling on ART 
because they were struggling to accept their HIV status; some still needed to 
confirm if they were HIV positive.  
               
                  “In fact I still want to be sure …from here…I will go back to test. If I still get the same 
result then I will take them (001)”. 
Seeking approval from spouses and other relatives 
Other women cited that they needed to go home and inform their partners or 
any other relatives first for approval. The other relatives were usually their 
mothers’ in law and grandmothers. 
    “ I was going to talk to my partner first. …he told me that there was some  
          traditional brew that he was going to give me I shouldn’t take them 
         (004)”. 
    
    “I want to go and tell them at home…My Grandmother (005).”  
 
DISCUSSIONS 
At Nhlangano public health Unit, HIV-infected pregnant woman are initiated the 
same day of booking. 64.3% HIV-infected pregnant women in our study 
population were booked and initiated during the second trimester. Most were 
single (79.6%), multiparous (75.5%) and attended secondary school (80.6%). 
The mean age was 25.4 years and 52% were employed. These findings are 
similar to antenatal care studies which were carried out in Nigeria23, Cape 
Town24 and Uganda25 where a large proportion of pregnant women in a similar 
age-group booked after the first trimester. 
In countries with a high prevalence of HIV infection, there is need for early 
booking of antenatal care; as soon as the woman knows that she is pregnant. 
This is of paramount importance and should be emphasized for early initiation 
so as to increase the duration of antiretroviral therapy given before delivery in 
order to reduce further maternofetal HIV transmission. 
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69 participants (70.4%) were adherent to treatment. This result is similar to the 
studies conducted in Ivory coast26 and India27 which revealed 74.3% and 73% 
respectively among HIV-infected patients; both with a reported adherence level 
of ≥ 95%. 
The regimen TDF-3TC-EFZ is effective. It increased the mean CD4 Count from 
554 to 709 with 95.6% of adherent participants in our study having 
undetectable viral load after 6 months. Studies over the effectiveness of highly 
active antiretroviral therapy among adults conducted in India21, sub-Saharan 
Africa28, a developing Caribbean country29 and Uganda30, mentioned viral 
suppression of 63.5 %, 78%, 82% and 85.2% respectively after 6 months. 
Also, some studies in a developing caribbean country29 and Uganda30, 31have 
indicated increment / improvement in CD4 count.   
Poor knowledge on HIV transmission, mother-to-child transmission and 
treatment, lack of effective counseling on ART, fear of side effects, use of 
alternative traditional medicine, challenges in accepting HIV status, seeking 
approval from spouses and other relatives are emerging themes for refusal of 
being initiated for treatment among HIV-infected pregnant women. These 
motives for refusal of initiation among HIV-infected pregnant women were also 
revealed in studies conducted in Zambia32, 33, Malawi34 and in Sub-sahara35. 
This study reveals and gives an indication of acceptance level, short term 
adherence and proportion of defaulter to the combined antiretroviral therapy 
among initiated HIV-infected pregnant women. It has also highlighted that good 
adherence is required for viral suppression. 
Furthermore, it gives us a better understanding of reasons for declining offers 
of initiation among HIV-infected pregnant women. Those findings can be 
transferred to similar context. 
This study has its limitations. We had a small size of patients. This may raise 
doubts if it’s used to generalize the findings. Some of the loss to follow-up 
patients could not be reached telephonically (either changed phone numbers or 
left the region). We couldn’t get more information. Quality of counseling before 
initiation was not explored so as to improve acceptance level. Our Viral load 
machine was only able to detect more than 100 copies although the chance of 
resistance to occur below this level in our setting is low. Our study only included 
treatment of naive patients. These results cannot, however, be extrapolated to 
treatment of experienced patients to nevirapine or AZT-3TC. 
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RECOMMENDATIONS 
 ANC initiation for all HIV-infected pregnant women should be treated as 
medically urgent. According to Swaziland and integrated HIV management 
guidelines (2015) and WHO (2010), every pregnant mother should start ANC 
during the first trimester of pregnancy.21,22 In the study, 63.9% booked at 2nd 
trimester. Programmes to improve health awareness and public enlightenment 
on right time for ANC enrolment should be implemented. 
To improve the acceptance rate, the Ministry of health should implement 
programs addressing barriers encountered by the HIV infected pregnant 
women. Initiatives to reduce prevailing stigma, educate the community on HIV 
related issues and empower women to take their own decisions should be 
taken. 
To improve patient retention, programs to improve service delivery and 
confidentiality should be implemented. For instance, pill count and provision of 
re-fills should be done at the same point by the same nurse. This saves on time 
and limits exposure on the long lines at the pharmacy and hence stigmatization.  
Also, outreach programs should be strengthened. Community health workers 
should be used to track and provide on-going counseling of the HIV-infected 
pregnant women starting from the positive diagnosis at antenatal care until after 
delivery. 
Furthermore, to improve the uptake of triple antiretroviral therapy and 
adherence to treatment, all HIV-infected pregnant women with CD4 Count 
above 350 should be given a comprehensive initial session of education on 
HIV, care and their health. Policy makers should strengthen the monitoring 
system of follow up visits of initiated pregnant women; the system should 
monitor clinical attendance or clinical appointment and ART adherence. In 
order to reduce the defaulter rate, there should be continuous adherence 
counseling and an effective system of tracing (phone calls or home visits).  
Before the expansion of option B+ programs, the provision of life long ARV 
treatment to HIV-infected pregnant women, the ministry of Health needs to 
address the mobility of patients with respect to self-transfers to minimize loss to 
follow-up. 
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CONCLUSION 
Most of the HIV infected pregnant women who visited the clinic accepted the 
treatment. After 6 months, more than two-third of the initiated participants were 
adherent and had undetectable viral loads. Antiretroviral therapy is effective 
and can be successfully initiated in pregnant women with CD4 count above 350 
but should be monitored closely to avoid loss to follow-up. Initiatives to reduce 
prevailing stigma, empower women and educate the community on HIV related 
issues should be implemented to realise the full potential of this program. 
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List of Appendices 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
TITLE OF THE RESEARCH PROJECT: Acceptance of and adherence to full 
antiretroviral therapy for prevention of mother to child transmission in HIV 
infected pregnant women with CD4 count above 350 at Nhlangano Health 
Centre, Swaziland. 
PRINCIPAL INVESTIGATOR: DR MANIGHULI KAMBASU NDAKIT 
ADDRESS: Nhlangano Health Centre 
                     P.O.BOX 29 
                     Nhlangano 
                     Ngwane Corner Street 
                     S400 
                     Swaziland 
CONTACT NUMBER:  +26876360461 
You are being invited to take part in a research project. Please take some time 
to read the information presented here, which will explain the details of this 
project. Please ask the study staff or doctor any questions about any part of this 
project so that you clearly understand what this research entails and how you 
could be involved. Also, your participation is entirely voluntary and you are 
free to decline to participate. If you say no, this will not affect you negatively in 
any way whatsoever. You are also free to withdraw from the study at any point, 
even if you do agree to take part. 
This study has been approved by the Health Research Ethics Committee at 
Stellenbosch University (South Africa) and will be conducted according to 
the ethical guidelines and principles of the international Declaration of Helsinki, 
South African Guidelines for Good Clinical Practice and the Medical Research 
Council (MRC) Ethical Guidelines for Research. 
Please read this document carefully and sign below if you agree to 
participate in the study. 
Setting, Participants and Responsibility 
A selection of Ministry of Health facilities are offering lifelong combined 
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antiretroviral therapy to all HIV positive pregnant women to prevent 
transmission of HIV infection from mother to child. This document is to help you 
understand the difference in your care that you will experience because of this.  
 
CD4 cells are a type of white blood cells that fight infection. CD4 count 
measures the number of CD4 cells in a sample of your blood; normal between 
500 and 1500 cells. Your CD4 count is a measure of the strength of your 
immune system and indicates the stage of your HIV disease and guides 
treatment. It also predicts your HIV disease progression; high CD4 count 
reduces complications of HIV disease and extends your life. 
When the CD4 count goes down, it means that HIV disease is progressing and 
the immune system is weakening and you are likely to fall sick. 
 
According to current national guidelines in Swaziland, if you have been 
diagnosed HIV positive and you are pregnant, you will be enrolled in the 
prevention from mother to child transmission (PMTCT) programme. In other 
health facilities, if your CD4 count is below 350, you would be offered combined 
anti-retroviral therapy as this provides the best protection for you and your 
baby. However if your CD4 is above 350, you would not be eligible for 
combined anti-retroviral therapy but would instead be offered preventive 
therapy to protect your baby from being infected with HIV. This preventive 
therapy involves a single anti-retroviral drug (AZT) for the mother during 
pregnancy, and a single anti-retroviral drug (nevirapine) for the infant until the 
end of breast feeding. 
 
The purpose of the study is to learn about how HIV positive pregnant women 
are taking the treatment to prevent HIV transmission to the child, to ensure that 
the treatment is protecting the baby from HIV.  
 
We recommend all HIV+ pregnant women to start combined anti-retroviral 
therapy because it has several benefits compared to preventive therapy with 
AZT. Our duty and your rights regarding your participation are stated below. 
 
 
Benefits 
 
Benefits of a life-long combined antiretroviral therapy compared to preventive 
therapy with AZT: 
 
 Treatment with ART regimen is simple and consists of one pill a day for 
you. Your baby will need to receive nevirapine syrup only for 6 weeks 
after delivery (compared to up to 18 months with preventive therapy) 
 Taking life-long ART reduces the risk of transmitting HIV to your sexual 
partner, if your partner is not infected with HIV. However, you should 
continue to use a condom during sexual intercourse for full protection. 
 Life-long ART started early in pregnancy might reduce the risk of infant 
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mortality (death of children less than one year) compared to preventive 
treatment with AZT, if your CD4 count is above 350. 
 ART started early in pregnancy might lower the risk of stillbirths (deaths 
of babies in the womb), prematurity (pre-term baby births) and maternal 
mortality (death of expecting mother) compared to preventive treatment 
with AZT. 
 Taking life-long ART reduces the risk of HIV transmission to the child of 
the next pregnancy. 
 The ART regimen provided is not known to cause anaemia (deficiency in 
quality of red blood cells), whilst preventive treatment with AZT, therapy 
carries a risk of inducing anaemia. 
 The ART regimen provided treats active hepatitis B (liver disease) 
infection. 
 
By participating to this study, you will benefit from a closer follow-up. Additional 
tests will be performed to assess HIV infection.  CD4 count at the start and 6 
months , viral load at the start and 6 months ,liver function tests at the start, one 
month,3 months,6 months, renal function at the start, one month,3 months and 
6 months. These tests will assist to identify problems with your treatment 
earlier. 
 
Risks 
 
Challenges/drawbacks of the life-long ART compared to preventive treatment: 
 
 Combined ART should be a life-long treatment that should preferably not 
be stopped. 
 Nightmares or dizziness may occur during the first two weeks but 
disappear in most of the cases. 
 The ART combination can rarely cause kidney and liver problems. You 
will be closely monitored in order to detect any problems as early as 
possible. If signs of toxicity are appearing the treatment will be changed. 
 
If you have any questions about PMTCT, please ask one of the nurses.  
Participating in this study does not require any treatment or intervention other 
than that you would normally undergo in the course of medical care as an HIV 
infected patient. You will have more regular blood tests; renal function tests, 
liver function tests,CD4 count test and viral load tests. These tests will have no 
anticipated negative effects on your health.  
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Confidentiality 
The data collected will remain anonymous, no name and addresses will be 
collected in the database and neither will be published in articles nor thesis. 
The personal information will only be accessible to individuals who are directly 
involved in your treatment (the staff of the health facility). These individuals are 
all under an oath of professional secrecy. To ensure complete and accurate 
transfer of your scientifically relevant data, selected researchers from the 
ministry of health, who are also under the oath of professional secrecy, may 
compare the collected data with your medical file. The members of the ethics 
commission may see medical data, but this data will be anonymised. 
Confidentiality will be strictly maintained during the entire study and beyond.  
If you accept to enter the study, your information will be collected and put in a 
database with no names; it is anonymous.  We will collect information about the 
antenatal care you receive, the birth of your baby, your postnatal care, your HIV 
follow-up care and information about your child up to 6 weeks after birth. You 
are eligible to be included in the study because you are attending Nhlangano 
Health Centre. Data collection will be carried out predominantly in this centre 
only. Decision to participate or not in the study will have no influence on the 
treatment you are offered. 
Most of the information required for the study is routinely collected for HIV 
pregnant women during the ante-natal and post-natal visits. We may ask for 
your opinion on the treatment you are taking. All information will be kept 
confidential and used only for purposes of the study. 
 As mentioned earlier your participation in this study is voluntary. You may 
withdraw from the study at any time without giving a reason. Your decision will 
not result in any loss of benefits regarding medical treatment – you will still 
have access to the full range of normal treatments.  
You will be informed of the results of the study through general information 
provided to health facilities and community leaders. 
Further information 
You should inform your family practitioner or usual doctor that you are taking 
part in a research study 
You should also inform your medical insurance company that you are 
participating in a research study 
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You can contact Dr  Manighuli Ndakit at 76360461 if you have any further 
queries or encounter any problems. 
You can contact the Health Research Ethics Committee (South Africa) at 
+27 219 389 207 if you have any concerns or complaints that have not been 
adequately addressed by your study doctor. 
You will receive a copy of this information and consent form for your own 
records 
 
Declaration by participant 
By signing below, I ………………………………agree to take part in a research 
study entitled Acceptance of and adherence to full antiretroviral therapy for 
prevention of mother to child transmission in HIV infected pregnant women with 
CD4 count above 350 at Nhlangano Health Centre, Swaziland. 
I declare that: 
 I have read or had read to me this information in the consent form and it 
is written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not 
been pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished if the study 
doctor or researcher feels it is in my best interests or if I do not follow the 
study plan as agreed to. 
 
Signed at (place)……………………on (date)…………………………………2014. 
 
Signature of participant                                       Signature of witness 
.......................................                                        .................................... 
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This is to be signed by patients who refuse the offer of HAART (PMTCT 
programme). 
Consent to an interview. 
I ……………………………………………………………………………………agree 
to an interview about why I do not want HAART. This is for a research study 
entitled Acceptance and adherence to full antiretroviral therapy for prevention of 
mother to child transmission in HIV infected pregnant women with CD4 count 
above 350 at Nhlangano Health centre, Swaziland. 
I declare that: 
 I have read or had read to me this information in this consent form and 
it is written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I refuse the offer of HAART. 
 I agree to an interview about why I do not want HAART. 
 This is voluntary; I have not been pressurised to take part. 
 
Signed at(place)…………………………on(date)……………………………2014 
 
Signature of participant                                       Signature of witness 
....................................                                           ................................... 
 
Declaration by investigator 
I  (name)…………………………………………………………………... declare 
that: 
 I explained the information in this document 
to………………………………………………………………… 
 I encouraged her to ask questions and took adequate time to answer 
them. 
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 I am satisfied that he/she adequately understands all aspects of the 
research as discussed above 
 I did/did not use an interpreter.(if an interpreter must sign the declaration 
below) 
 
 
Signed at(place)…………………………on(date)……………………’2014 
 
Signature of investigator                      Signature of witness 
........................................                        .................................... 
Declaration by interpreter 
 
I  (name)…………………………………………………………....declare that: 
 I assisted the investigator 
(name)……………………………………………………to explain the 
information in this document to (name of 
participant)…………………………………………………………. using the 
language medium of Siswati. 
 We encouraged her to ask questions and took adequate time to answer 
them. 
 I am satisfied that the participant fully understands the content of this 
informed consent document and has had all her questions satisfactorily 
answered. 
 
Signedat(place)………………………...on(date)……………………………….2014 
 
Signature of interpreter                      Signature of witness 
.......................................                        .................................. 
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QUESTIONNAIRE 
PART 1-Demographic Data 
NAME…………………………………………………………………………………….
. 
AGE:……………………………………………………….........................................                                                       
 Physical 
address…………………………………………………………….…………… 
RELIGION:  
 Christian  
 
 
 Islam 
 
 
 Other 
 
EMPLOYMENT STATUS: 
 Employed :     Self-employed     Not Self- 
employed  
 
 
 Unemployed  
 
 
 
MARITAL STATUS: 
 Single  
 
 
 Married 
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 Separated 
 
 
 Divorced 
 
 
 Widowed  
EDUCATION LEVEL 
 None 
 
 Primary 
 
 
 Secondary/High school 
 
 
 Tertiary/University 
                   
 
PART 2 
 
1. Are you aware about how HIV is transmitted? 
..............................................................................................................................
..............................................................................................................................
..............................................................................................................................
..............................................................................................................................
.................................... 
2. Do you know the benefits of taking ARVs while pregnant? 
……………………………………………………………………………………………
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……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
………………………… 
3. What do you think about the PMTC   campaign? 
..............................................................................................................................
..............................................................................................................................
..............................................................................................................................
..............................................................................................................................
.................................... 
4. Before being tested, you were counselled? In the counselling process, were 
all your concerns addressed on PMTCT? 
..............................................................................................................................
..............................................................................................................................
..............................................................................................................................
..............................................................................................................................
........................................................ 
5. What do you feel about participating in the PMTCT programme? 
..............................................................................................................................
..............................................................................................................................
..............................................................................................................................
..............................................................................................................................
....................................……………. 
6. Why are you not accepting the offer of medication for the rest of your life? 
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………………………………………………………………………
……………………………… 
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